Protective Effect of Minocycline Against Cisplatin-induced Ototoxicity

Chi-Kyou Lee, MD · Jang-In Shin, PhD1 · Yang-Sun Cho, MD2

Department of Otorhinolaryngology-Head and Neck Surgery, Cheonan Hospital, Soonchunhyang University School of Medicine, Cheonan; 1Medical Laser Research Center, Dankook University, Cheonan; 2Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Objectives. Cisplatin, a widely used chemotherapeutic agent, has serious side effects, including nephrotoxicity and ototoxicity. Minocycline is a semisynthetic second-generation tetracycline that exerts anti-inflammatory and neuroprotective effects. The purpose of this study was to elucidate the protective effect of minocycline against cisplatin-induced ototoxicity in the auditory hair cell.

Methods. The House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line and guinea pigs were used for in vitro and in vivo experiments. Cells were exposed to cisplatin with or without pre-treatment with minocycline. Cell survival was analyzed using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). Whole-cell lysates were collected and immunoblotted with antibodies against Bcl-2, p-c-Jun, active caspase-3, cleaved poly (ADP-ribose) polymerase (PARP), and apoptosis-inducing factor (AIF). The guinea pigs received intraperitoneal injections of cisplatin alone or following minocycline pretreatment. The auditory brainstem response was tested and the cochleae were harvested and evaluated using scanning electron microscopy.

Results. Survival significantly increased in cells pretreated with minocycline compared with cells exposed to cisplatin alone. Cisplatin treatment increased the expression of active caspase 3, p-c-Jun, PARP, and AIF, and pretreatment with minocycline attenuated this response. In animal study, the threshold shift by cisplatin injection in the auditory brainstem response was less pronounced in animals pretreated with minocycline. Scanning electron microscopy revealed more severe damage to the outer hair cells at the basal and middle turns than the apical turn.

Conclusion. Minocycline partially protects against cisplatin-induced ototoxicity via both caspase-dependent and independent apoptosis pathways.

Key Words. Minocycline, Hair cell, Apoptosis, Caspase

INTRODUCTION

Cisplatin is an important and effective antineoplastic agent that inhibits several types of malignant neoplasms. DNA is believed to be the target of the antineoplastic activity because cisplatin binds irreversibly to DNA, forming intra-strand crosslinks between adjacent guanine residues. Cisplatin has severe side effects that limit its clinical use; these include otoxicity, nephrotoxicity, and neurotoxicity. Though the mechanism mediating the nephrotoxicity and otoxicity is unknown, it is believed to be different from that involved in the drug’s anti-tumor activity. The most commonly reported histopathological manifestation of otoxicity is outer hair cell (OHC) degeneration. However, the otoxic effects of cisplatin are not limited to the auditory hair cells, and the stria vascularis and spiral ganglion cells are also affected (1). Cisplatin-induced ototoxicity is related to changes in the antioxidant activity in the hair cells, particularly the OHCs.
Mitochondrial dysfunction caused by reactive oxygen species has been implicated in the pathogenesis of cisplatin-induced ototoxicity (3). Boulikas and Vogiouka (4) reviewed that cisplatin directly induced apoptosis in auditory sensory cells through mitochondrial apoptotic pathways. The Bcl-2 family, cytochrome c, and caspase 3 are important elements in the caspase-dependent pathway, and apoptosis-inducing factor (AIF), poly (ADP-ribose) polymerase (PARP), and c-Jun N-terminal kinase (JNK) play critical roles in the caspase-independent pathway. AIF, a mitochondrial intermembrane protein, triggers apoptosis when it is released into the cytosol. Various strategies have been developed in the laboratory setting to prevent ototoxicity, though they are not widely used clinically.

Minocycline is a tetracycline derivative used as an antimicrobial agent to treat conditions such as acne. Many studies have confirmed the anti-inflammatory and neuroprotective properties of minocycline (5). Minocycline inhibits caspase-1 and caspase-3, which are involved in the generation of interleukin-1 and the induction of apoptosis, respectively (6). Wang et al. (7) reported that, in addition to protecting neural cells, minocycline protected non-neuronal kidney epithelial cells against various agents inducing apoptosis through the enhancement of Bcl-2 expression. Corbacella et al. (8) investigated the effect of minocycline on gentamicin (GM)-induced ototoxicity, and reported that minocycline inhibited p38 MAP kinase phosphorylation and caspase 3 activation.

As cisplatin is commonly used for anti-tumor chemotherapy, its ototoxic effect is still a problem for those who suffer from malignant tumors. The aim of the present study was to investigate the protective effect of minocycline on cisplatin induced ototoxicity and to identify the possible mechanism of action in vivo and in vitro.

**METHODS**

**In vitro experiments**

**Cell culture**

House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS) at 33°C under 5% CO2 in an incubator. In all experiments, 70-80% confluent cultures were used.

**Cell viability assay**

The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was used to measure HEI-OC1 cell viability after each treatment. HEI-OC1 cells were seeded at 105 cells/mL in 96-well plates and were maintained in DMEM with 10% FBS at 33°C with 5% CO2 in air. They were exposed to various concentrations of minocycline (Sigma-Aldrich Corp., St. Louis, MO, USA) for 24 hours to determine the proper concentration for the protection experiment. We then selected the 10 µM (4.59 µg/mL) of minocycline for further experiments, which was most protective and less toxic concentration for HEI-OC1 cells (Fig. 1A). Cells were divided into four groups: control, minocycline (mino), cisplatin (cis), and minocycline plus cisplatin (mino-cis). Minocycline was administered 24 hours before cisplatin treatment. Cisplatin was diluted repeatedly using the same volume of media, and the cells were incubated in the various concentrations for 24 hours. MTT solution (2 mg/mL in phosphate-buffered saline [PBS]) was added (50 µL/well) after incubation and plates were further incubated for 2 hours at 33°C in 5% CO2 in air. The MTT solution was then removed and 100 µL dimethylsulfoxide (DMSO; Kanto Chemical Co., Tokyo, Japan) was added. After stirring the plate using a microplate mixer (Amersham, Pharmacia Biotech, Buckinghamshire, UK), the absorbance at a wavelength of 540 nm was measured using a microplate reader (BIO-RAD 550, Bio-Rad, Hercules, CA, USA). The percentage of cell viability was calculated using the following equation: Cell viability (%) = 100 - (1 - absorbance/absorbance_control) * 100.

---

**Fig. 1.** (A) Cell survival curve of House Ear Institute-Organ of Corti 1 (HEI-OC1) cells cultured with minocycline. Minocycline (mino) is cytotoxic at high, but not at low, concentrations. (B) Cell survival curve of HEI-OC1 cells cultured with cisplatin alone and with cisplatin (cis) after minocycline pretreatment. More cells survived in the 10 µM minocycline pretreatment condition compared with the cisplatin alone condition.
The animals were divided into three groups. Group 1 (6 animals) received an intraperitoneal injection (i.p.) of minocycline (45 mg/kg) and received cisplatin (15 mg/kg, i.p.) 12 hours later, group 2 (6 animals) received cisplatin (15 mg/kg, i.p.) and normal saline in an equal volume to the minocycline, and group 3 (3 animals) received minocycline (45 mg/kg, i.p.) and normal saline in an equal volume to the cisplatin. All chemicals were obtained from Sigma (St. Louis, MO, USA).

Auditory tests
The auditory brainstem response (ABR) was performed using a computer-based signal averaging system (Tucker-Davis Technology, Alachua, FL, USA) to determine the auditory threshold. ABR was performed prior to drug administration and every 24 hours for 5 days after drug treatment. An active electrode lead was positioned subcutaneously at the vertex and referred to the second electrode in the left infra-auricular area. The ground electrode was located on the contralateral ear. ABRs were recorded in an electrically shielded, double-walled sound booth in response to clicks and tone bursts at 8, 16, and 32 kHz. Each response was averaged over a total of 500 times. Intensities were expressed in dB sound pressure level (SPL) peak equivalent, based on calibration. Sounds were presented in 10 dB steps, and ABR responses were recorded for each intensities. ABR threshold was defined as the lowest intensity capable of eliciting a replicable, visually detectable wave V.

Scanning electron microscopy
Immediately after the completion of the follow-up ABRs, animals were decapitated and the cochleae were harvested. Cochleae were immediately immersed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer. Small holes were made in the apex and the round and oval windows. The cochleae were fixed using a perilymphatic perfusion of 2.5% glutaraldehyde in 0.1 M cacodylate buffer and were refrigerated overnight in the same solution. The following day, after rinsing with cacodylate buffer, the cochleae were postfixed with a slow perfusion of 1% osmium tetroxide in 0.1 M cacodylate buffer. The bony capsule of the cochlea was thinned using a dental drill. The remaining bone and lateral wall were dissected away using fine forceps and a 26 gauge needle to expose the organ of Corti. Dissected cochleae were dehydrated in serially increasing concentrations of ethanol from 50-100%, and were critical point-dried. Cochleae were mounted on SEM stubs and were sputter-coated with platinum. Fully processed specimens were examined and photographed using a Hitachi S-3000N scanning electron microscope (Hitachi, Tokyo, Japan).

Statistical analysis
Statistical evaluation of the results was performed using SPSS ver. 10.0 (SPSS Inc., Chicago, IL, USA) with the significance level set at P<0.05. For comparison of the toxicity with serial doses of cisplatin in cell culture experiments, log rank test was
RESULTS

In vitro experiments

Cell viability assay
Minocycline was cytotoxic at high, but not at low concentrations (Fig. 1A). Cisplatin was toxic in a dose-dependent manner and pretreatment with minocycline significantly decreased cisplatin-induced toxicity at the concentrations between 0.5 and 16 µg/mL (log rank test, \( P < 0.05 \)). No protective effect of minocycline was observed at higher concentrations of the drug (Fig. 1B).

Western blot analysis

Effect of minocycline on the caspase-dependent pathway: Bcl-2, and caspase 3
To determine whether minocycline inhibited cisplatin-induced caspase activation, cells were exposed to 4 µg/mL and 8 µg/mL cisplatin in the presence or absence of 10 µM minocycline. Cleaved caspase-3 expression increased in HEI-OC1 cells exposed to cisplatin of two different concentrations by 2.22 (4 µg/mL) and 2.32 (8 µg/mL) times as the control. Pretreatment with minocycline attenuated expression of cleaved caspase-3 by half in response to 4 µg/mL, but not 8 µg/mL of cisplatin. The expression of Bcl-2 was elevated by 2.3 (4 µg/mL cisplatin) and 1.98 (8 µg/mL cisplatin) times respectively when minocycline was added to the cisplatin-treated cells (Fig. 2).

Effect of minocycline on the caspase-independent pathway: JNK, PARP, and AIF
JNK and PARP play important roles in the caspase-independent cell death pathway. To evaluate the role of the pathway in cisplatin-induced apoptosis in HEI-OC1 cells, we measured the expression of p-c-JUN and PARP. The expression of p-c-JUN increased by 3.21 (4 µg/mL) and 15.0 (8 µg/mL) times, in a dose-dependent manner, in the cis group. The expression was markedly attenuated by minocycline pretreatment to the level of 2.26 (4 µg/mL) and 8.04 (8 µg/mL) times as the control. The expression of cleaved PARP also increased by 8.19 (4 µg/mL) and 16.98 (8 µg/mL) times, in a dose-dependent manner, in the cis group. The expression markedly decreased by minocycline pretreatment to the level of 1.67 (4 µg/mL) and 1.11 (8 µg/mL) times as the control when minocycline was administered (Fig. 2).

Fig. 2. Cells pretreated with 10 µM minocycline and cultured in 4 µg/mL or 8 µg/mL cisplatin were analyzed using the Western blotting technique with antibodies targeting Bcl-2, p-JUN, cleaved caspase-3, cleaved polymerase (PARP), and AIF. Bcl-2 expression was elevated after the pretreatment with minocycline. Minocycline pretreatment decreased cisplatin-induced cleaved caspase 3 activity at the 4 µg/mL, but not the 8 µg/mL dose. The expression of p-JUN, cleaved PARP, and apoptosis-inducing factor (AIF) increased by cisplatin treatment, and suppressed by minocycline pretreatment.

Fig. 3. The distribution (A) and mean amount (B) of hearing threshold shift in each group. The shift was greater in group 2 (white circle) than it was in group 1 (black circle). The threshold shift in the 16 Hz tone burst significantly different between the two groups. The threshold shift was less than 10 dB in two animals pretreated with minocycline.
In vivo experiments

Auditory brainstem response
No change in hearing was observed in the minocycline-treated animals (group 3). The threshold elevation in group 1 was generally lower than that of group 2. Two animals (33%) in group 1 even did not show any threshold shift. A significant protective effect of minocycline pretreatment was found for the 16 kHz tone (Mann-Whitney test, \( P < 0.05 \)) (Fig. 3).

SEM evaluation
Morphological evaluation of the SEM sections revealed that the basal and middle turns were more severely damaged than the apical turn. The inner hair cells were relatively well preserved in all turns compared with the OHCs in both groups 1 and 2 (Fig. 4). However, more OHCs survived in group 1 compared with group 2. No morphological change was observed in SEM section of animals treated with minocycline (group 3).

DISCUSSION

It is well known that two mitochondrial apoptotic pathways exist, the caspase-dependent and caspase-independent pathways. Caspase 3, the Bcl family, and cytochrome c (Cyt c) play important roles in the caspase-dependent pathway. PARP-1-mediated cell death is caspase-independent and is considered to be "regulated necrosis" because it lacks many of the morphological features of classic apoptosis. Zong et al. (9) recently reported that in regulated necrosis, the cell actively initiates its death program following PARP-1 hyperactivation. Furthermore, it has been reported that JNK, particularly JNK1, is required for PARP-induced mitochondrial dysfunction inducing AIF translocation and subsequent cell death (10). AIF is an essential downstream element in PARP-1-mediated cell death. It moves into the nucleus and triggers nuclear DNA fragmentation which is an irreversible step in cell death.

Minocycline had been reported to prevent cell death by at least two mechanisms: attenuation of innate and adaptive immunity and blockade of apoptotic cascades (5). Minocycline attenuates immunity through inhibition of microglial activation and proliferation, involving caspase-1, inducible nitric oxide synthetase, and cyclooxygenase 2. Additionally, minocycline inhibits adaptive immunity by reducing the expression of MMPs (11-14). Minocycline inhibits caspase-dependent and -independent cell death induced by different stimuli in vitro, such as glutamate, hydrogen peroxide, and tumor necrosis factor alpha (TNF-\( \alpha \)) (15, 16). Up regulation of Bcl-2 produces a protective effect by antagonizing Bax and Bid, a family of death-promoting factors that elicit the release of Cyt c through the outer mitochondrial membrane (7). Alano et al. (17) reported that PARP-1 enzymatic activity can be directly inhibited by tetracycline derivatives and minocycline was the most potent among them. JNK has been reported to have an important role in this apoptotic pathway (10, 18).

To determine the mechanism underlying minocycline protection against cisplatin-induced ototoxicity, we examined cleaved caspase-3, Bcl-2, cleaved PARP, AIF, and JNK, which are important elements in the caspase-dependent and independent pathways.

Cleaved caspase 3 activity was also elevated following exposure to cisplatin. Although addition of minocycline elevated Bcl-2 activity after treatment with both concentrations of cisplatin, it could suppress cleaved caspase 3 activity stimulated only by lower, but not higher concentration of cisplatin. These findings indicate that minocycline does not effectively inhibit caspase-dependent apoptosis stimulated by a high concentration of cisplatin.

HEI-OC1 cells expressed high levels of p-JUN, cleaved PARP, cleaved caspase-3 and AIF (Fig. 5). These data indicate that minocycline inhibits different apoptotic pathways in HEI-OC1 cells and suggest that minocycline activates Bcl-2 and decreases cleaved caspase-3, poly (ADP-ribose) polymerase (PARP), apoptosis-inducing factor (AIF) activity, and mitigates the release of cytochrome c from the mitochondria.

Fig. 5. The cisplatin-induced apoptosis pathway in House Ear Institute-Organ of Corti 1 (HEI-OC1) cells and the proposed mechanism mediating the protective effect of minocycline. The black arrow (↑) indicates activation, and the blocked arrow head (↓) indicates inhibition. Our data show that minocycline activates Bcl-2 and decreases cleaved caspase-3, poly (ADP-ribose) polymerase (PARP), apoptosis-inducing factor (AIF) activity. These findings and those of previous studies suggest that minocycline activates Bcl-2 and inhibits downstream caspase-3 in the caspase-dependent pathway, and suppresses PARP-1 and downstream AIF in the caspase-independent pathway.
and AIF, which are in the caspase-independent pathway following exposure to 4 µg/mL and 8 µg/mL cisplatin. The increased expression of p-JUN and cleaved PARP decreased by 30-40% with pre-treatment with 10 µM minocycline. The expression of AIF also decreased by 20-40%. These findings suggest that minocycline inhibits PARP activity in the cell nucleus, followed by down regulation of JNK and AIF in the cytoplasm (18) (Fig. 5). Collectively, it can be suggested that cisplatin can induce ototoxicity through two discrete pathways simultaneously, and that these pathways can partially be protected by minocycline.

The in vivo experiments revealed that the shift in hearing threshold caused by cisplatin administration was partially attenuated by minocycline pretreatment. No change in hearing was observed in two animals of group 1. These results suggest the protective role of minocycline against cisplatin ototoxicity. Though a significant protection was observed only at 16 kHz, this partial effect can be attributed to the small number of animals tested.

Evaluation of the SEM sections revealed that pretreatment with minocycline partially protected the OHCs at the basal and middle turn of the organ of Corti. The morphology of the OHCs was nearly normal in two animals that did not show a shift in the ABR threshold, and the animals with a significant hearing loss showed less severe morphological changes than those treated with cisplatin-alone. The diversity of the protective effect of minocycline may be explained by the difference of drug-host interactions or susceptibility to cisplatin. Moreover, other studies suggest that cisplatin-induced ototoxicity in vitro may be mediated by high-mobility group 1 (HMG1), inducible nitric oxide synthase (iNOS), Na⁺, K⁺-ATPase, and Ca²⁺-ATPase and these various mechanisms of action, not protected by minocycline, may account for the differing responses to minocycline (19, 20).

In conclusion, minocycline may partially protect against cisplatin-induced ototoxicity in vitro and in vivo. Our findings suggest that both caspase-dependent and independent pathways are involved in cisplatin-induced ototoxicity and also in the protective mechanism by minocycline.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Hamers FP, Klis SF, Gispen WH, Smoorenburg GF. Application of a neuroprotective ACTH(4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs. Eur Arch Otorhinolaryngol. 1994;251(1):23-9.
2. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol. 1995 Jun;76(6):386-94.
3. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol. 2001 Dec;12(12):2683-90.
4. Boulitas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level: review. Oncol Rep. 2003 Nov-Dec;10(6):1663-82.
5. Domerçq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004 Dec;25(12):609-12.
6. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801.
7. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem. 2004 May 7;279(19):19948-54.
8. Corbaccella E, Lanzoni I, Ding D, Previtali M, Salvi R. Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear Res. 2004 Nov;197(1-2):11-8.
9. Zong WX, Ditsworth D, Bauer DE, Wang ZX, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004 Jun 1;18(11):1272-82.
10. Xu Y, Huang S, Liu ZG, Han J. Poly(ADP-ribose)-ribosene polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRA2β-mediated JNK1 activation. J Biol Chem. 2006 Mar 31;281(13):8788-95.
11. Yrjanheikki J, Keinanen R, Pelilikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15769-74.
12. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14669-74.
13. Tikka T, Fiebich BL, Goldstein G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001 Apr 15;21(8):2580-8.
14. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308.
15. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8.
16. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington’s disease. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10483-7.
17. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9685-90.
18. Alano CC, Swanson RA. Players in the PARP-1 cell-death pathway: JNK1 joins the cast. Trends Biochem Sci. 2006 Jun;31(6):309-11.
19. Cheng PW, Liu SH, Hsu CJ, Lin-Shiau SY. Correlation of increased activities of Na+, K+-ATPase and Ca²+-ATPase with the reversal of cisplatin ototoxicity induced by D-methionine in guinea pigs. Hear Res. 2005 Jul;205(1-2):102-9.
20. Li G, Liu W, Frenz D. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology. 2006 Jan;27(1):22-30.